Institutional shares held 118 Million
5.9K calls
53K puts
Total value of holdings $2B
$99K calls
$894K puts
Market Cap $1.56B
94,339,296 Shares Out.
Institutional ownership 125.57%
# of Institutions 108


Latest Institutional Activity in CNTA

Top Purchases

Q3 2024
Siren, L.L.C. Shares Held: 3.26M ($54M)
Q3 2024
T. Rowe Price Investment Management, Inc. Shares Held: 3.56M ($58.9M)
Q3 2024
Perceptive Advisors LLC Shares Held: 6.28M ($104M)
Q3 2024
Avidity Partners Management LP Shares Held: 2.13M ($35.3M)
Q3 2024
Deep Track Capital, LP Shares Held: 1.35M ($22.4M)

Top Sells

Q3 2024
Eco R1 Capital, LLC Shares Held: 3.22M ($53.4M)
Q3 2024
Morgan Stanley Shares Held: 1.38M ($22.9M)
Q3 2024
Pfm Health Sciences, LP Shares Held: 269K ($4.46M)
Q3 2024
Balyasny Asset Management LLC Shares Held: 681K ($11.3M)
Q3 2024
Octagon Capital Advisors LP Shares Held: 2.01M ($33.3M)

About CNTA

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.


Insider Transactions at CNTA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
817K Shares
From 12 Insiders
Grant, award, or other acquisition 367K shares
Exercise of conversion of derivative security 450K shares
Sell / Disposition
1.24M Shares
From 14 Insiders
Payment of exercise price or tax liability 364K shares
Open market or private sale 875K shares

Track Institutional and Insider Activities on CNTA

Follow Centessa Pharmaceuticals plc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CNTA shares.

Notify only if

Insider Trading

Get notified when an Centessa Pharmaceuticals PLC insider buys or sells CNTA shares.

Notify only if

News

Receive news related to Centessa Pharmaceuticals plc

Track Activities on CNTA